April 24th 2024
George R Simon, MD, FACP, FCCP on selecting ALK inhibitors in ALK-positive non–small cell lung cancer.
July 13th 2022
George Simon, MD, FACP, FCCP, discusses the evaluation of datopotamab deruxtecan in TROP-2–overexpressing solid tumors.